Abstract 275P
Background
In 2022, the U.S. Food and Drug Administration (FDA) approved Lutetium-177 Prostate-specific membrane antigen (Lu-177 PSMA). This approval was based on the VISION trial, in which Lu-177 PSMA demonstrated improved progression-free survival (PFS) and overall survival (OS) compared to standard therapy alone. PSMA is more strongly expressed in prostate cancer than in benign prostatic hyperplasia and correlates with Gleason Score and cancer grade. PSMA is involved in tumor growth by activating IP3K-AKT-mTOR signaling through folate metabolism. PSMA expression is suppressed by androgen receptor (AR) bound complexes with testosterone and promoted by unbound AR. In other words, inhibition of AR signaling enhances PSMA expression. These findings suggest that PSMA is involved in the mechanism of resistance to treatment in castration resistant prostate cancer (CRPC). Our previous study also showed that CRPC patients with PSMA expression in the blood circulating tumor cells (CTCs) have a shorter PFS. In this study, we aimed to determine the association between PSMA expression in CTCs and OS after the initiation of taxane-based chemotherapies in metastatic CRPC.
Methods
Forty-eight patients with metastatic CRPC treated with docetaxel followed by cabazitaxel were included in the study. PSMA expression in CTCs was analyzed over time, and the association between PSMA expression and OS was analyzed.
Results
Twenty-seven patients were positive for PSMA expression, and 21 patients were negative for PSMA expression in CTC. The analysis comparing patient backgrounds showed no significant differences with respect to Gleason Score, number of docetaxel treatments, prior ARATs administration, or metastatic site. On the other hand, patients with positive PSMA showed a longer time to acquire castration resistance. The log-rank test result showed shorter OS after initiation of docetaxel treatment in patients with positive PSMA than in those with negative PSMA (median survival at observation, PSMA-positive group: 618 days; PSMA-negative group: 1187 days; P=0.05).
Conclusions
The expression of PSMA in CTCs was associated with OS after initiation of taxane-based chemotherapy in metastatic CRPC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract